Fast Five Quiz: Breast Cancer Myths

Pavani Chalasani, MD, MPH


April 20, 2021

Recent data showed that some postmenopausal women may be able to avoid adjuvant chemotherapy. The RxPONDER study found that postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one to three positive nodes and a 21-gene RS ≥ 25 (Oncotype DX) derived no further benefit from chemotherapy that was added to endocrine therapy. However, premenopausal patients with the same clinical characteristics saw a 45% relative risk reduction in invasive disease–free survival events.

Evidence suggests that chemotherapy does offer survival benefits for women aged 70 years or older with TNBC. A recent study found that older women with TNBC who received chemotherapy had significantly improved survival compared with those who were recommended to undergo chemotherapy but did not receive it.

Read more about treatment of locally advanced and inflammatory breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.